{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:47:28Z","timestamp":1762660048599,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["R25DA035163, K23DA044085"],"award-info":[{"award-number":["R25DA035163, K23DA044085"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["R01DA046527, P30DA040500"],"award-info":[{"award-number":["R01DA046527, P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10461-021-03220-0","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T14:04:08Z","timestamp":1616421848000},"page":"2591-2598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["HIV Pre-exposure Prophylaxis and Buprenorphine at a Drug Detoxification Center During the Opioid Epidemic: Opportunities and Challenges"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-620X","authenticated-orcid":false,"given":"Sabrina A.","family":"Assoumou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha M.","family":"Paniagua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curt G.","family":"Beckwith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura F.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Coogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"issue":"9883","key":"3220_CR1","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet"},{"issue":"10","key":"3220_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa022164","volume":"349","author":"PJ Fudala","year":"2003","unstructured":"Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949\u201358.","journal-title":"N Engl J Med"},{"issue":"22","key":"3220_CR3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1001\/jama.2019.6390","volume":"321","author":"DK Owens","year":"2019","unstructured":"USPSTF, Owens DK, Davidson KW, et al. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA J Am Med Assoc. 2019;321(22):2203\u201313.","journal-title":"JAMA J Am Med Assoc"},{"key":"3220_CR4","unstructured":"Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142017 update: a clinical practice guideline. March 2018. https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2017.pdf. Accessed on 12 June 2020."},{"issue":"5","key":"3220_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynski J, O\u2019Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009. Am J Public Health. 2013;103(5):917\u201322.","journal-title":"Am J Public Health"},{"issue":"2","key":"3220_CR6","first-page":"CD002207","volume":"2008","author":"RP Mattick","year":"2008","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2008(2):CD002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"3220_CR7","first-page":"CD002209","volume":"2009","author":"RP Mattick","year":"2009","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):CD002209.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3220_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jsat.2007.08.004","volume":"35","author":"LE Sullivan","year":"2008","unstructured":"Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine\/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35(1):87\u201392.","journal-title":"J Subst Abuse Treat"},{"issue":"16","key":"3220_CR9","first-page":"443","volume":"64","author":"C Conrad","year":"2015","unstructured":"Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"3220_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2105\/AJPH.2019.305366","volume":"110","author":"C Alpren","year":"2020","unstructured":"Alpren C, Dawson EL, John B, et al. Opioid use fueling HIV transmission in an urban setting: an outbreak of HIV infection among people who inject drugs\u2014Massachusetts, 2015\u20132018. Am J Public Health. 2020;110(1):37\u201344.","journal-title":"Am J Public Health"},{"issue":"1","key":"3220_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12889-018-6314-8","volume":"19","author":"AR Bazzi","year":"2019","unstructured":"Bazzi AR, Drainoni ML, Biancarelli DL, et al. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions. BMC Public Health. 2019;19(1):31.","journal-title":"BMC Public Health"},{"issue":"1","key":"3220_CR12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/ADM.0b013e3181d41ddb","volume":"5","author":"HK Knudsen","year":"2011","unstructured":"Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21\u20137.","journal-title":"J Addict Med"},{"key":"3220_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.drugalcdep.2016.02.044","volume":"164","author":"I Kuo","year":"2016","unstructured":"Kuo I, Olsen H, Patrick R, et al. Willingness to use HIV pre-exposure prophylaxis among community-recruited, older people who inject drugs in Washington, DC. Drug Alcohol Depend. 2016;164:8\u201313.","journal-title":"Drug Alcohol Depend"},{"issue":"14","key":"3220_CR14","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1080\/10826084.2020.1823419","volume":"55","author":"SM Walters","year":"2020","unstructured":"Walters SM, Kral AH, Simpson KA, Wenger L, Bluthenthal RN. HIV pre-exposure prophylaxis prevention awareness, willingness, and perceived barriers among people who inject drugs in Los Angeles and San Francisco, CA, 2016\u20132018. Subst Use Misuse. 2020;55(14):2409\u201319.","journal-title":"Subst Use Misuse"},{"key":"3220_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"Supplement_5","key":"3220_CR16","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1093\/infdis\/jiaa162","volume":"222","author":"SA Assoumou","year":"2020","unstructured":"Assoumou SA, Paniagua SM, Linas BP, et al. Rapid versus laboratory-based testing for HIV and hepatitis C at a drug detoxification treatment center: a randomized trial. J Infect Dis. 2020;222(Supplement_5):S376\u201383.","journal-title":"J Infect Dis"},{"key":"3220_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugalcdep.2016.02.024","volume":"162","author":"A Caudarella","year":"2016","unstructured":"Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug Alcohol Depend. 2016;162:51\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"3220_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2019.09.003","volume":"107","author":"RL Snow","year":"2019","unstructured":"Snow RL, Simon RE, Jack HE, Oller D, Kehoe L, Wakeman SE. Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: a qualitative study of a bridge clinic. J Subst Abuse Treat. 2019;107:1\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"3220_CR19","doi-asserted-by":"publisher","first-page":"xiii","DOI":"10.1016\/j.idc.2020.06.016","volume":"34","author":"SA Springer","year":"2020","unstructured":"Springer SA, Del Rio C. Addressing the intersection of infectious disease epidemics and opioid and substance use epidemics. Infect Dis Clin N Am. 2020;34(3):xiii\u2013xiv.","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"3220_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13722-017-0092-y","volume":"12","author":"PD Friedmann","year":"2017","unstructured":"Friedmann PD, Suzuki J. More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addict Sci Clin Pract. 2017;12(1):29.","journal-title":"Addict Sci Clin Pract"},{"key":"3220_CR21","unstructured":"HIV Prevention Trials Network. HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV. https:\/\/www.hptn.org\/news-and-events\/press-releases\/hptn-083-study-demonstrates-superiority-cabotegravir-prevention-hiv. Accessed on 10 Aug 2020."},{"key":"3220_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.drugalcdep.2018.08.014","volume":"195","author":"SG Sherman","year":"2019","unstructured":"Sherman SG, Schneider KE, Park JN, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148\u201355.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"3220_CR23","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/09540121.2019.1587356","volume":"31","author":"KB Biello","year":"2019","unstructured":"Biello KB, Edeza A, Salhaney P, et al. A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs. AIDS Care. 2019;31(10):1214\u201320.","journal-title":"AIDS Care"},{"issue":"9","key":"3220_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA J Am Med Assoc. 2019;321(9):844\u20135.","journal-title":"JAMA J Am Med Assoc"},{"issue":"10","key":"3220_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/09540121.2019.1601669","volume":"31","author":"JL Barreras","year":"2019","unstructured":"Barreras JL, Linnemayr SL, MacCarthy S. \u201cWe have a stronger survival mode\u201d: exploring knowledge gaps and culturally sensitive messaging of PrEP among Latino men who have sex with men and Latina transgender women in Los Angeles, CA. AIDS Care. 2019;31(10):1221\u20137.","journal-title":"AIDS Care"},{"issue":"Suppl 1","key":"3220_CR26","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/QAI.0b013e3182920126","volume":"63","author":"GM Wingood","year":"2013","unstructured":"Wingood GM, Dunkle K, Camp C, et al. Racial differences and correlates of potential adoption of preexposure prophylaxis: results of a national survey. J Acquir Immune Defic Syndr (1999). 2013;63(Suppl 1):S95\u2013101.","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"issue":"37","key":"3220_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.15585\/mmwr.mm6837a2","volume":"68","author":"D Kanny","year":"2019","unstructured":"Kanny D, Jeffries WL IV, Chapin-Bardales J, et al. Racial\/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men\u201423 urban areas, 2017. MMWR Morb Mortal Wkly Rep. 2019;68(37):801\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"3220_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.annepidem.2017.02.003","volume":"27","author":"KL Hess","year":"2017","unstructured":"Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27(4):238\u201343.","journal-title":"Ann Epidemiol"},{"issue":"5","key":"3220_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/archinternmed.2010.541","volume":"171","author":"DP Alford","year":"2011","unstructured":"Alford DP, LaBelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425\u201331.","journal-title":"Arch Intern Med"},{"issue":"1","key":"3220_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-019-0139-3","volume":"14","author":"ME Godersky","year":"2019","unstructured":"Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, Tsui JI. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. Addict Sci Clin Pract. 2019;14(1):11.","journal-title":"Addict Sci Clin Pract"},{"key":"3220_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90\u20136.","journal-title":"J Subst Abuse Treat"},{"key":"3220_CR32","unstructured":"National Library of Medicine (U.S.). (2021) A study comparing oral buprenorphine and injectable buprenorphine for the treatment of opioid use disorder (VA-BRAVE). Identifier NCT04375033. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04375033?term=injection+buprenorphine&recrs=ab&draw=2&rank=2."},{"issue":"2","key":"3220_CR33","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.idc.2018.02.001","volume":"32","author":"BL Norton","year":"2018","unstructured":"Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of chronic hepatitis C in patients receiving opioid agonist therapy: a review of best practice. Infect Dis Clin N Am. 2018;32(2):347\u201370.","journal-title":"Infect Dis Clin N Am"},{"issue":"4","key":"3220_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/jamapsychiatry.2017.4614","volume":"75","author":"TC Green","year":"2018","unstructured":"Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405\u20137.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"3220_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11904-019-00436-7","volume":"16","author":"L Fanucchi","year":"2019","unstructured":"Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV\/AIDS Rep. 2019;16(1):1\u20136.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"8","key":"3220_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11606-010-1311-3","volume":"25","author":"CW Shanahan","year":"2010","unstructured":"Shanahan CW, Beers D, Alford DP, Brigandi E, Samet JH. A transitional opioid program to engage hospitalized drug users. J Gen Intern Med. 2010;25(8):803\u20138.","journal-title":"J Gen Intern Med"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-021-03220-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-021-03220-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T14:28:26Z","timestamp":1624458506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-021-03220-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["3220"],"URL":"https:\/\/doi.org\/10.1007\/s10461-021-03220-0","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"type":"print","value":"1090-7165"},{"type":"electronic","value":"1573-3254"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"5 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}